FDA approves Pfizer drug combo for more men with prostate cancer
The FDA has approved Pfizer's drug talazoparib, taken with enzalutamide, for more men with prostate cancer. It now covers men whose cancer has spread but still responds to hormone therapy. Patients need certain gene mutations. In a trial of 599 men, it cut the risk of the cancer worsening or death by 52%. Anemia was the top serious side effect.
Where this came from. One outlet reported this. We read it, then wrote the sixty words above.